Kuros Biosurgery AG

Development of biomaterials combined with bioactives for tissue regeneration and repair

Kuros Therapeutics AG was established in June 2000 to commercialize therapeutical products based on Proffessor Jeffrey Hubbel’s technology (see below). The company was derived from the Swiss Federal Institute of Technology (ETH) and the University of Zurich. Kuros Therapeutics was sold to Straumann AG in February 2002, which separated the non-dental sector from the main company to become Kuros Biosurgery AG.

Kuros collaborates i.a. with Baxter Healthcare and the Swiss Federal Institute of Technology.

Didier Crowling, CEO
Edward Currie, Dr., COO
Virginia Jamieson, Dr., Medical Director
Michael Bavand, Dr., Director of Technology & Operations
Marion Bavand, Dr. Director of Regulatory Affairs & Quality Assurance

Fritz Kunz, Chairman
Hervé de Kergrohen, Dr.
Arnd Kaltofen, Dr.
Claudio Nessi, Dr.
Jeffrey Hubbell, Prof.
Dominik Ellenrieder
Didier Cowling

Jeffrey Hubbell, Prof.
Norbert Boos, Dr.
Cato T. Laurencin, Dr.
Ralph Müller, Prof.
Sabine Werner, Prof.
Thomas Steffen, Prof.

Technoparkstrasse 1
8005 Zurich
Switzerland
Phone: +41-(0)44-200-56-00
Fax: +41-(0)44-200-57-00

Kuros focuses on the regeneration of injured tissue by promoting tissue re-growth, the reconstruction of the functional activity by implantations and the localised treatment using therapeutics. The company’s technology is based on the combination of natural or synthetic matrices that vary in their consistencies and other specific properties, and linked bioactives to stimulate tissue re-growth. Kuros is engaged in the stimulation of cell infiltration by integrating additional cell binding or cell signalling molecules into the base matrix.

Kuros’ technology covers a broad range of medical application fields including spinal surgery, dermatology, drug delivery, infection and pain control, etc.

In January 2005, Kuros commenced a Phase I clinical trial in the treatment of distal radial compression fractures. In 2004, Kuros started multi-center Phase I/Iia clinical trials in the treatment of chronic wounds. The treatment of spinal fusion is currently in the pre-clinical phase; the treatment of long bone fractures ahs entered Phase I clinical trial.
Kuros’ technology is also tested in Clinical Phase I/II trieals in the fields of spinal orthopaedics, diabetic and venous ulcers.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.